ER antagonists have demonstrated excellent curative efficacy in patients with ER-positive breast cancer (37); while ovarian cancer is also hormone-driven, the expression and role of hormone receptors in its pathogenesis remain poorly elucidated. The gene discussed is NR4A1; the disease is ovarian carcinoma.